drugset / Trial / NCT06040489

Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly

NCT06040489

Phase 2/3 Unknown 100 enrolled University of Brasilia
RandomizedParallel-groupOpen-labelTreatment

Summary

Randomised clinical trial comparing oral miltefosine associated with pentoxifylline to intravenous liposomal amphotericin b for the treatment of cutaneous and mucosal leishmaniasis

Timeline

Start
2022-06-22
Primary completion
2024-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amphotericin B Unknown 25 mg/kg Intravenous
Comparator Amphotericin B Unknown 40 mg/kg Intravenous
Subject Miltefosine Small molecule 50 mg Oral
Subject Pentoxifylline Small molecule 400 mg Oral